Ameliorating the Role of Aripiprazole in Memory Deficits Induced by Intracerebroventricular Streptozotocin-Induced Dementia of Alzheimer’s Type

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder causing immense suffering for the patients. Dopamine D2 and 5-hydroxytryptamine receptor 1A (5-HT1A) receptors’ activation has been reported to play crucial role in managing neurological outcomes brain other health disorders. This study aimed investigate of aripiprazole, dopamine 5-HT1A selective activator, restoration memory deficit induced by streptozotocin mice. The cognitive functions animals were determined using Morris water maze. Brain sections stained with hematoxylin eosin Congo red examine structural deviations. oxidative stress (thiobarbituric acid reactive substance glutathione), acetylcholinesterase activity, IL-6, IL-10 measured assess biochemical alterations. Activation aripiprazole attenuated STZ-induced deficit, increased GSH levels, reduced TBARS AChE IL-6 levels prevented anomalies Hence, present concluded that mitigated impairment can be used as an efficacious therapeutic target management AD.